Z. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am J Physiol Renal Physiol 304: F1317-F1324, 2013. First published March 6, 2013 doi:10.1152/ajprenal.00536.2012.-Early diagnosis of diabetic nephropathy (DN) is difficult although it is of crucial importance to prevent its development. To probe potential markers and the underlying mechanism of DN, an animal model of DN, the db/db mice, was used and serum and urine metabolites were profiled using gas chromatography/time-of-flight mass spectrometry. Metabolic patterns were evaluated based on serum and urine data. Principal component analysis of the data revealed an obvious metabonomic difference between db/db mice and controls, and db/db mice showed distinctly different metabolic patterns during the progression from diabetes to early, medium, and later DN. The identified metabolites discriminating between db/db mice and controls suggested that db/db mice have perturbations in the tricarboxylic acid cycle (TCA, citrate, malate, succinate, and aconitate), lipid metabolism, glycolysis, and amino acid turnover. The db/db mice were characterized by acidic urine, high TCA intermediates in serum at week 6 and a sharp decline thereafter, and gradual elevation of free fatty acids in the serum. The sharp drop of serum TCA intermediates from week 6 to 8 indicated the downregulated glycolysis and insulin resistance. However, urinary TCA intermediates did not decrease in parallel with those in the serum from week 6 to 10, and an increased portion of TCA intermediates in the serum was excreted into the urine at 8, 10, and 12 wk than at 6 wk, indicating kidney dysfunction occurred. The relative abundances of TCA intermediates in urine relative to those in serum were suggested as an index of renal damage. diabetic nephropathy; metabonomics; tricarboxylic acid cycle; gas chromatography mass spectrometry
DIABETIC MELLITUS (DM) IS a group of chronic metabolic diseases characterized by high blood glucose levels, which is likely to result in end-stage renal disease (ESRD), which affects approximately one-third to one-fifth of all diabetic patients (23, 29) . Diabetic nephropathy (DN), a leading cause of ESRD, is considered the most severe complication of DM, with a high risk of atherosclerotic disease and premature death. Chronic kidney disease is associated with an 8-to 10-fold increase in cardiovascular mortality and is a risk multiplier in patients with diabetes and hypertension (7) . The downhill course from normoalbuminuria to ESRD proceeds through the intermediate stages of micro-or macroalbuminuria (24) . DN occurs in 30%-40% of patients with type 1 diabetes mellitus (T1DM) after 20 yr and in 15-20% of patients with type 2 diabetes mellitus (T2DM) (19) . Microalbuminuria is considered a major risk factor for DN and progressive renal insufficiency in diabetes (3, 36) , and it is used clinically as a reference indicator for the early diagnosis of DN. However, studies have suggested that microalbuminuria is neither a sensitive nor a specific predictor of DN (28) . Clinically, renal biopsies are often conducted to confirm the final pathological diagnosis (6, 21) . Although renal biopsy has generally been accepted as a useful approach to nephrological diagnoses, its invasiveness, potential damage, and complications (including hematuria, perirenal hematoma, and infection) greatly reduce its application. Therefore, a noninvasive and sensitive method is required for the diagnosis of early DN.
In addition to microalbuminuria, the range of renal injury biomarkers has been expanded to a set of urine proteins, cytokines, and genes. Several potential biomarkers, such as serum ␤ 2 -microG, high sensitivity C-reaction protein (hsCRP), cystatin C (Cys C), hyaluronic acid (HA), laminin (LN), and tissue inhibitor of metalloproteinases 1 (TIMP-1), have been suggested as additional indicators of DN (20) , but no further clinical application of them has yet been reported. In contrast, based on novel genomic studies, several gene candidates, including NEGR1, IRS2, RIPK2, and SHPK, have been recognized as involved in kidney damage, suggesting that they encode common underlying factors that predispose individuals to kidney disease through functional and structural changes in the renal glomerulus and tubules (31) . In recent years, genetic studies using different animal models have shown that DNassociated genetic loci are often the genes that also underlie insulin resistance, obesity, hyperlipidemia, and cardiovascular diseases (11, 22) , suggesting that the metabolic disorders involved in DM alter gene expression and predispose patients to renal complications. However, no specific gene has been associated with a large proportion of patients with DN. The lack of consistency and any link between these various genes have led to a failure to identify a genetic biomarker (5) .
Recently, metabonomics has been applied to the evaluate DM-and DN-related diseases (9, 17, 18, 32, 33) . These studies suggested potential markers of DM-and DN-related diseases, such as the nonesterified fatty acids and esterified fatty acids, lipids, acyl-carnitines, acyl-glycines, and metabolites related to tryptophan metabolism. Because elevated glucose of diabetes is the high-risk factor of DN, the metabolism of glucose and its downstream metabolism may play a key role in trigging the occurrence of DN. However, few studies have focused on the downstream metabolism of glycolysis, e.g., TCA cycles, except a report on the T1DM DN rats induced by streptozotocin (39) . Although T1DM had higher rate (30 -40%) to develop to DN than T2DM (ϳ15% develops to DN), the number of T2DM is 10 times as many as that of T1DM. Therefore, many more DN patients derive from T2DM, instead of T1DM. In this study, a model of T2DM animal, the well-known db/db mouse model based on the C57BLKS/J strain, was used as the animal model of DN, because these mice inevitably progress from diabetes to DN (obesity, hyperglycemia, hyperinsulinemia, and renal damage; Ref. 2) and have lesions consistent with DN (15, 25) . Both the serum and urine were collected in the diabetic stage, around 6 wk old, up until the early stage of DN, around 8 to 9 wk old, and to DN (12 wk or older). All the samples were analyzed by gas chromatography/time-of-flight mass spectrometry (GC/TOFMS) and evaluated using an established metabonomic platform (14) . We monitored the time-related metabonomic changes in the db/db mice to identify the perturbed metabolic pathways and potential biomarkers of early stage DN.
MATERIALS AND METHODS
Materials and reagents. Myristic-1,2-13 C2 acid, 99 atom% 13 C, the stable-isotope-labeled internal standard compound, methoxyamine hydrochloride (purity 98%), standard alkane solution (C8-C40), and pyridine (Ն99.8% GC) were purchased from Sigma-Aldrich (St. Louis, MO). N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) plus 1% trimethylchlorosilane (TMCS) were provided by Pierce Chemical (Rockford, IL). Urease was obtained from Sigma. Methanol and n-heptane were HPLC grade and obtained from Tedia (Fairfield, OH) and Merck (Darmstadt, Germany), respectively. Purified water was produced by a Milli-Q system (Millipore, Bedford, MA).
Animals, samples, and biochemical measurement. A total of 80 C57BL/Ks db/db (n ϭ 40, male) and db/m mice (n ϭ 40, male) were obtained from Research Institute of Nephrology (Jingling Hospital, Nanjing) and housed in a temperature-and humidity-controlled environment with a 12-h light/dark cycle for 20 wk. The mice were all fed with a standard chow (GB 14924. 2-2001 and GB 14924.3-2001 ; China Experimental Animal Food Standard) throughout the experiments. All animals were allowed free access to food and water except as otherwise noted.
Urine samples were collected for 12 h at 6, 8, 10, 12, and 16 wk of age in metabolic cages (SuzhouFengshi Laboratory Animal Equipment, Jiangsu, China) individually. Blood samples were collected in a gel tube at 6, 8, 10, 12, and 16 wk of age immediately after the urine collection and centrifuged to prepare serum after collection. Animal experiments were conducted under the approval of Animal Ethics of China Pharmaceutical University. All these samples were prepared and stored at Ϫ80°C until use. Serum glucose and albumin excretion were measured using an automatic biochemical analyzer according to the manufacturer's instructions (Powerwave 200; Bio-Tek Instruments, Winooski, VT).
Sample preparation and derivatizaiton. Urine and serum samples were preprocessed, extracted, and derivatized as previously reported (1, 13) . Briefly, urine and serum were thawed by incubation at 37°C for 20 min before use. For serum samples (50 l), 200 l of methanol containing internal standard [ 13 C2]myristic acid (12.5 g/ml) were added to it and then the solution was vigorously extracted for 3 min and was centrifuged with the SORVALL BiofugeStratos centrifuge (Sollentum, Germany) at 20,000 g for 10 min at 4°C. An aliquot of 100 l supernatant was transferred to a GC vial and then evaporated to dryness using SPD2010-230 SpeedVac Concentrator (Thermo Savant, Holbrook, NY). For urine samples, after centrifuging at 1,600 g for 10 min, an equal volume of urease (20 IU) solution was added to 50 l urine. The mixtures were then incubated at 37°C for 45 min to decompose the excess urea in them. Thirty microliters of supernatant were transferred to a GC vial and then evaporated to dryness under vacuum. Thirty microliters of methoxyamine in pyridine (10 mg/ml) were added to the dried residue and vigorously vortex mixed for 2 min. The methoximation reaction was carried out for 16 h at room temperature, followed by trimethylsilylation for 1 h by addition of 30 l of MSTFA with 1% TMCS as the catalyst. At last, the solution was vortex mixed again for 30 s after the external standard methyl myristate in heptane (30 g/ml) was added to each GC vial for GC/MS analysis.
GC/TOFMS analysis. The analytes in serum and urine were chromatographically separated in an Agilent 6890 GC equipped with a 10 m ϫ 0.18 mm inner diamteter fused-silica capillary column chemically bonded with 0.18 m DB5-MS stationary phase (J&W Scientific, Folsom, CA). The injection temperature was set to 250°C, and helium was used as the carrier gas at a constant flow rate of 1.0 ml/min through the column. The initial column temperature was maintained at 70°C for 2 min and was raised up to 305°C at a rate of 35°C/min (for serum samples) or 30°C /min (for urine samples). The column effluent was introduced into the ion source of a Pegasus III MS (Leco, St. Joseph, MI). The transferline temperature was set at 250°C and the ion source temperature at 200°C. Ions were generated by a 70-eV electron beam at a current of 3.0 mA. Masses were acquired with m/z 50 -680 at a rate of 30 spectra/s.
GC/TOFMS data analysis and compound identification. Automatic peak detection and mass spectrum deconvolution using the ChromaTOF software (version 3.25; Leco) were performed at a peak width of 2 s. Peaks with signal-to-noise ratios Ͻ20 were rejected. To obtain accurate peak areas for the internal standard and specific peaks/compounds, the data were processed as reported previously (14, 16) . The retention index of each peak was calculated by comparing the retention time of the peak with those of an alkane series (C 8-C40). Identification of compounds was made by comparing the mass spectra and retention index of all detected compounds with authentic reference standards and those available in libraries of mainlib and publib of the National Institute of Standards and Technology (NIST) library 2.0 (2008), Wiley 9 and the in-house mass spectra library database established by Umeå Plant Science Center (Umeå University, Sweden).
Principal component analysis and statistical analysis. The relative quantitative result (peak areas) of all the detected peaks was firstly normalized by the internal standard compound (myristic-1,2-13 C2 acid) before multivariate statistic analysis using SIMCA-P 11 software (Umetrics, Umeå, Sweden). Urinary data were further weighed by urinary volume (34) . The final data matrix, X, was constructed with normalized peak areas, with two vectors: sample names as observations in the first column, and retention times/peaks as the response variables in the first row. Here, principal component analysis (PCA) and partial least squares projection to latent structures and discriminant analysis (PLS-DA) were employed to process the acquired GC/TOFMS data. Samples from the same groups were classified into one for PLS-DA modeling. The result of PCA and PLS-DA was displayed as scores plots that visualized the clustering of the samples and indicated the similarity of samples. The closer clustering of the samples represented higher compositional similarity, whereas the further clustering represented diverse metabonomic composition. The purpose of PLS-DA was to calculate models differentiating groups and identify the response variables contributing most to the model and further identify potential markers of DN. The goodness of fit for a model is evaluated using three quantitative parameters; i.e., R 2 X is the explained variation in X, R 2 Y is the explained variation in Y, and Q 2 Y is the predicted variation in Y. The range of these parameters is between 0 and 1, the closer they approached 1, the better they could predict or explain. Cross-validation with seven cross-validation groups was used throughout to determine the number of principal components (8, 35) , and the number of principal components was determined once the Q 2 Y value decreased continuously. Permutation tests were performed with 100 iterations to validate the model. The univariate statistical analysis was performed using one-way analysis of variance, with a significance level of 0.01 or 0.05.
Peak area is expressed as the means Ϯ SD. The Student's t-test for unpaired data was used to compare db/db group and db/m group. Meanwhile, the receiver-operating characteristic (ROC) analysis was conducted using SPSS (version 15.0; IBM) and R platform (version 2.12.1).
RESULTS
Biochemical parameters. The biochemical parameters of the db/m controls remained at rather stable levels from 6 to 16 wk of age, whereas the db/db mice showed significant differences in their body weight and serum glucose levels on 6 wk (Table 1) , suggesting T2DM occurred at the early time. However, the urinary albumin excretion did not show obvious difference between db/db and db/m at week 6. Consistent with previous reports (38) , on week 8, db/db mice had obvious elevated urinary albumin excretion rate (AER), indicating early DN occurred. As the db/db mice grew up, the increasing urinary albumin amount and decreasing glomerular filtration rate confirmed that these db/db mice provided an excellent animal model of DN from early to later stage. We also measured the pH value of the urine at different time points. Interestingly, our results revealed that the pH value of urine of the db/db mice became abnormally acidic with the passage of time (Table 1) .
Serum and urine metabolic fingerprints of db/m and db/db mice. The GC/TOFMS profiles of the metabolites in the serum and urine samples from the db/m and db/db mice produced one chromatogram for each sample. To check the stability of the analysis system, standard deviations of both the internal standard ([ 13 C2]myristic acid) and the external standard (methyl myristate) were evaluated. We observed fairly good reproducibility for the two standards in serum samples (Ͻ5%), but the standard deviations were larger in urine samples (Ͻ25%), because urine samples were either diluted or concentrated depending on the urinary volumes of each mice. Visual inspection of typical ion chromatograms showed distinctly different serum fingerprints (Supplemental Fig. S1 , A and C; Supplemental Material for this article is available online at the Am J Physiol Renal Physiol website) and urine fingerprints (Supplemental Fig. S1, B and D) for the db/m and db/db mice. In the serum, 230 peaks were detected and 61 of them were identified (Supplemental Table S1 ). The serum metabolites that discriminated the db/m mice and db/db mice in the chromatograms included 3-hydroxybutyrate, citrate, lysine, arachidonic acid, and cholesterol. In the urine samples, 119 peaks were detected and 48 metabolites were identified (Supplemental Table S2 ). Peaks such as those for succinate, malate, 3-hydroxybutyrate, and allantoin showed obvious variations in height between the db/m and db/db mice.
Metabolic pattern of the db/db mice. The acquired GC/ TOFMS data were first normalized by the internal standard and then subject to multivariate statistic analysis. Two separate PLS-DA models were calculated, based on either the serum or urine data. According to cross-validation, the serum model explained 55.6% and predicted 40.5% of the sample variation in Y (sample types) and explained 45.3% of the variation in X, i.e., the GC/TOFMS response variables (R 2 X ϭ 0.45, R 2 Y ϭ 0.56, and Q 2 Y ϭ 0.41, respectively). The urine model explained 58.3% of the variation in X (R 2 X ϭ 0.58, R 2 Y ϭ 0.54, and Q 2 Y ϭ 0.36, respectively). The metabolic profiles of the two models revealed a distinct trajectory for the db/db data between the ages of 6 and 16 wk (Fig. 1) , whereas the normal control db/m data clustered closely. The scores plots for both the db/db serum and urine started from the top of the plot, close to the plot for the normal db/m controls, and gradually moved towards the left and then down, further away from the normal db/m controls. This obvious time-dependent metabolomic pattern indicated continuous metabolic modifications in the db/db mice, conferred by pathological insult and aging. The trajectory scores plot (Fig. 1 ) matches with different stages from T2DM (6 wk), to early DN (8 -10 wk), and late stage DN (16 wk), as defined previously (11) .
Metabolic features of db/db mice at different stages. The db/db mice displayed distinct metabonomic differences to the db/m mice at different pathological stages. In addition, as the development of DN, db/db mice showed distinct metabolic perturbation from that of db/m both in serum and urine from weeks 6 to 8, 10, 12, and 16 (Supplemental Fig. S2 ). The metabolic variations between the db/db and db/m mice confirm the metabolic perturbation in the db/db animals, whereas the continuous metabolic changes in the db/db mice from early to late stage disease suggest different metabolic features at different stages of the disease. Identification of the affected metabolites in the serum included tricarboxylic acid cycle intermediates, free fatty acids (FFAs), amino acids, and organic acids in the db/db group relative to the db/m control (Supplemental Tables S3 and 4 ). In detail, serum levels of five TCA intermediates (fumarate, citrate, ␣-ketoglutarate, malate, and succinate) were markedly higher in the db/db mice at 6 -8 wk of age relative to the control values, although succinate did not show the same tendency, (Supplemental Table S3 and Fig. 2A) . Notably, there was a sharp drop of the TCA intermediates (fumarate, citrate, ␣-ketoglutarate, and malate) in db/db mice from week 6 to 8 (relative to db/m; Fig. 2A ). Of the FFAs measured in the serum, the saturated FFAs (hexadecanoic acid and tetradecanoic acid) were significantly higher at weeks 8 and 10 in the db/db mice, whereas the levels of unsaturated FFAs (9-octadecenoic acid and octadecadienoic acid) were only significant higher at week 10, compared with those of the db/m controls ( Table 2 and  Supplemental Table S3 ). Generally, the amino acids fluctuated dramatically in the db/db mice during the whole experiment. Among the 20 amino acids measured in the serum, the levels of lysine in the db/db mice declined markedly at weeks 8, 10, 12, and 16 (Table 2) .
In the urine, the gradual elevation of malate and stable citrate were noted from weeks 6 -8, 10 , and 12, in contrast to a decline of them in serum (Table 2 ; Fig. 2B ). Succinate showed a similar time-dependant tendency both in serum and urine. However, in urine four TCA intermediates (malate, succinate, citrate, and cis-aconitate) were dramatically lower in the db/db mice than in the db/m controls at the end of week 16 ( Table 2 and Fig. 2) . The relative concentrations of TCA intermediates in urine to those in serum increased significantly from weeks 6 to 8 and 10 and declined then after in Fig. 3 . Among the six organic acids measured in the urine, the ketobody, 3-hydroxybutyrate was higher in the db/db mice at weeks 6, 8, 10, 12 , and 16, whereas the others were generally lower than in the control mice.
Potential markers correlating to the clinic index of urinary albumin excretion. The urinary and serum metabolites were correlated to AER by Pearson correlation analysis (Table 3) , as clinical doctors may be interested in the corelationship. Remarkably, significant correlation was observed between AER and acids, such as 2-oxoisocaproic acid, citrate, cis-aconitate, succinate, gluconate, glutarate and glycine, ␤-alanine, and ethanolamine, in the urine of db/db mice (Table 3 and Supplemental Fig. S4 ). In serum, the changes of AER positively correlated with erythritol and negatively correlated with me- tabolites including arginine, decanoic acid, hexadecanoic acid, methionine, tetradecanoic acid, lysine, myo-inositol, and 5-hydroxytryptamine in db/db mice. It was suggested that these metabolites had the potential to provide complementary data to AER in facilitating the diagnosis of DN.
ROC analysis of TCAs. To evaluate the validity of diagnosing DN based on TCA levels, the ROC analysis of TCA intermediates in serum and urine were processed, respectively. Area under curves (AUC) ranging from 0.604 to 0.732 at the best cut-off point were obtained from TCAs in the serum (Fig. 4A and Table 4) . Meanwhile, the AUCs of TCAs in urine varied from 0.595 to 0.638, respectively (Fig. 4B and Table 4 ). In general, the AUCs of 0.847 and 0.927 were acquired with a combination of five TCAs in serum and three TCAs in urine, respectively.
DISCUSSION
Previous studies on animal models and clinic patients of DN have revealed the perturbed metabolic pathways involving glycolysis, lipid metabolism, and amino acid turnover (4, 9, 27, 40) . However, the crucial metabolic perturbation contributing most to the underlying mechanism of DN remains elusive. Urinary metabolites indicate the function of kidney, and while serum metabolites reflect the metabolic status of the whole system, comparative analysis of the metabolites in serum and urine may provide useful information to suggest the functioning of kidney. Consistent with a previous study using the diabetic nephropathy rats induced by streptozotocin (39), the elevated urinary TCAs were also observed in db/db mice. Moreover, this study simultaneously profiled TCA intermediates in serum and urine and evaluated the dynamic changes of TCA patterns in db/db mice accompanying the progress of DN. Based on the well model of db/db mice of different stages of DN, for the first time, this study revealed that the db/db mice were characterized by distinguished acidic urine, high TCA intermediates in serum at week 6, and a sharp decline thereafter. On the contrary, urinary TCA intermediates did not decrease in parallel with those in the serum from week 6 to 10. The contradictionary tendency of TCAs in serum and urine may be an indicator of renal dysfunction, which is discussed below. The results are consistent whether we use urine volume or urine creatinine as standardization method. Considering that elevated glucose is a high-risk factor of DN, analysis of metabolites involved in glycolysis and the subsequent TCA cycle is of crucial importance to approach the underlying mechanism of DN. Compared with LC/MS and NMR, GC/MS is a more sensitive tool for analyzing organic acids, such as TCA intermediates and amino acids after their trimethyl-silylation, although the high level of glucose greatly challenged metabolomic profile of the metabolites in serum and urine of db/db mice. The excessive glucose decreased chromatographic efficiency, and the overloaded peak of glucose covered a fairly long section of chromatogram (RT from 350 s to 400 s; Supplemental Fig. S1, C and D) , muffling the metabolites eluted within this section. Consequently, the metabolites fell into this section were not well distinguished after the baseline noise was removed, and less metabolites were identified with GC/TOFMS system than our previous analysis (37) . Fortunately, for most amino acids, free fatty acids and TCA intermediates, GC/TOFMS analysis showed the good sensitivity in detecting the metabolites in the serum and urine samples containing redundant glucose. Thanks to the strategy of hydrolysis of excessive urea and trimethyl-silylation of the metabolites, GC/TOFMS analysis profiled and identified more low-weight acidic molecules than previous analysis on cell lines, serum, and urine involved in diabetes (26, 37, 39) .
Relative abundances of serum TCAs to glucose in db/db mice. The levels of serum TCA intermediates reflected the metabolic status of the TCA cycle, whereas the ratios of the TCA intermediates to glucose in the serum indicated efficient energetic metabolism of glucose. The significantly higher serum levels of citrate, malate, ␣-ketoglutarate (and fumarate to a lesser extent, but not succinate, Fig. 2 ) at 6 wk suggest a greatly accelerated TCA cycle in the db/db mice, indicating normal glucose metabolism at this stage. However, we observed a sharp drop in serum TCA intermediates at week 8 (relative to week 6; Fig. 2) , and a gradual decline from week 10 to weeks 12 and 16, when the glucose levels gradually increased, indicating that less glucose was fed into the TCA cycle or that the metabolism of glucose via the TCA cycle was less efficient. With the development of diabetes and the occurrence of insulin resistance, which is usually observed in T2DM patients, glycolysis is obstructed, leading to downregulation of the TCA cycle. A less efficient TCA cycle would further increase the glucose levels. These distinct metabolic features of db/db mice reflect the metabolic processes that may be involved in the development of diabetes and DN. Similar circumstances was found in peripheral nerve system of db/db mice studied by Hinder et al. (10) .
Interestingly, succinate was the only TCA intermediate to show a tendency different from those of the other intermedi- ates. A previous study identified a paracrine signaling pathway in the kidney in which high levels of glucose directly triggered the release of the prohypertensive hormone renin. This signaling cascade was involved in the local accumulation of succinate and the activation of its receptor GPR91 in the kidney (30) . Consistent with this, we found that succinate was the only serum TCA intermediate that gradually increased from week 6 to weeks 8, 10, and 12, and this tendency coincided with the onset of DN symptoms. In contrast, the levels of the other TCA intermediates showed a very sharp drop from week 6 to weeks 8, 10, and 12 (Fig. 2) .
Relative abundances of urinary TCA intermediates to those in serum. TCA intermediates can usually be detected in the urine of rats. Their levels reflect the balance between their excretion by the renal glomerulus and their reabsorption in the renal tubules. At week 6, although very high levels of TCA intermediates were present in the serum, only small amounts (relative to those at weeks 8, 10, and 12) were detected in the urine. These results indicated that either their excretion was controlled or that they were reabsorbed back into the renal tubules, suggesting the normal function of kidney at this stage, week 6. As the level of glucose kept growing from week 6 to weeks 8, 10 , and 12, the amounts of TCA intermediates in the urine did not decline (Fig. 2B ) in parallel with their decline in the serum ( Fig. 2A) at weeks 10 to 12. The comparable or equivalent amounts of TCA intermediates in the urine at weeks 10 and 12 to that at week 6 to 8 is inconsistent with their much lower levels in the serum (weeks 8, 10, and 12) and gradually decreased glomerular filtration rate, indicating that renal dysfunction occurred. Therefore, the level of TCA intermediates (especially for citrate and malate) in the urine relative to that in the serum may be an indicator of kidney function (Fig. 3) , and a potential measure for the early diagnosis of DN. 
